150 related articles for article (PubMed ID: 25211301)
1. Vorapaxar (Zontivity) for prevention of thrombotic cardiovascular events.
Med Lett Drugs Ther; 2014 Sep; 56(1451):85-6. PubMed ID: 25211301
[No Abstract] [Full Text] [Related]
2. Vorapaxar (Zontivity) for the Prevention of Thrombotic Cardiovascular Events.
Barry KA; Somerville NJ
Am Fam Physician; 2015 Aug; 92(4):304-5. PubMed ID: 26280236
[No Abstract] [Full Text] [Related]
3. Vorapaxar: first global approval.
Poole RM; Elkinson S
Drugs; 2014 Jul; 74(10):1153-63. PubMed ID: 24962425
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
6. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
7. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
[TBL] [Abstract][Full Text] [Related]
8. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
French SL; Arthur JF; Tran HA; Hamilton JR
Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
[TBL] [Abstract][Full Text] [Related]
9. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
Serebruany VL; Fortmann SD; Rao SV; Tanguay JF; Lordkipanidze M; Hanley DF; Can M; Kim MH; Marciniak TA
Thromb Haemost; 2016 May; 115(5):905-10. PubMed ID: 26887783
[TBL] [Abstract][Full Text] [Related]
10. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
12. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
Moschonas IC; Goudevenos JA; Tselepis AD
Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
[TBL] [Abstract][Full Text] [Related]
13. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Moon JY; Franchi F; Rollini F; Angiolillo DJ
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
[TBL] [Abstract][Full Text] [Related]
14. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
15. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Shinohara Y; Goto S; Doi M; Jensen P
J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
[TBL] [Abstract][Full Text] [Related]
16. Vorapaxar in atherosclerotic disease management.
Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
[TBL] [Abstract][Full Text] [Related]
17. State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Du M; Chase M; Oguz M; Davies G
Curr Med Res Opin; 2017 Sep; 33(9):1535-1543. PubMed ID: 28277861
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
[TBL] [Abstract][Full Text] [Related]
19. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Duerschmied D; Bode C
Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]